ISSN:
1468-2982
Source:
Blackwell Publishing Journal Backfiles 1879-2005
Topics:
Medicine
Notes:
In six European clinics 111 migraine patients were treated in a series of open dose-ranging studies with subcutaneous injections of 1 to 4 mg GR43175, a novel 5-HT1-like receptor agonist. Response rates after 20–30 min were dose related and rose from 33% with 1 mg to 96% with 4 mg GR43175. Side effects were minor and transient. These promising results warrant confirmation in placebo-controlled double-blind trials.
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1111/j.1468-2982.1989.tb00076.x